Ignat Drozdov
Research Subjects
Research Interests
Ignat Drozdov has a total of 402 co-authors. Here are the top co-authors by number of shared publications:
Mark Kidd
Wren Laboratories, Branford, CT, USA
30 shared publications- Irvin M. Modlin
Yale School of Medicine
24 shared publications - Mark Kidd
Wren Laboratories
22 shared publications Lisa Bodei
Memorial Sloan Kettering Cancer Center, New York, NY, USA
13 shared publications- Lisa Bodei
Department of Radiology, Memorial Sloan Kettering Cancer Center
13 shared publications - Manuel Mayr
Imperial College London
12 shared publications
Latest Publications
- Open Access
- 18 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0314145
Early detection of heart failure using in-patient longitudinal electronic health records
Heart Failure (HF) is common, with worldwide prevalence of 1%-3% and a lifetime risk of 20% for individuals 40 years or older. Despite its considerable health economic burden, techniques for early detection of HF in the general population are sparse. In this work we tested the hypothesis that a simple Transformer neural network, trained on comprehensive collection of secondary care data across the general population, can be used to prospectively (three-year predictive window) identify patients at an increased risk of first hospitalisation due to HF (HHF). The model was trained using routinely-collected, secondary care health data, including patient demographics, A&E attendances, hospitalisations, outpatient data, medications, blood tests, and vital sign measurements obtained across five years of longitudinal electronic health records (EHRs). The training cohort consisted of n = 183,894 individuals (n = 161,658 age/sex-matched controls and n = 22,236 of first hospitalisation due to HF after a three-year predictive window). Model performance was validated in an independent testing set of n = 8,977 patients (n = 945 HHF patients). Testing set probabilities were well-calibrated and achieved good discriminatory power with Area Under Receiver Operating Characteristic Curve (AUROC]) of 0.86, sensitivity of 36.4% (95% CI: 33.33%-39.56%), specificity of 98.26% (95% CI: 97.95%-98.53%), and PPV of 69.88% (95% CI: 65.86%-73.62%). At Probability of HHF ≥ 90% the model achieved 100% PPV (95% CI: 96.73%-100%) and sensitivity of 11.7% (95% CI: 9.72%-13.91%). Performance was not affected by patient sex or socioeconomic deprivation deciles. Performance was significantly better in Asian, Black, and Mixed ethnicities (AUROC 0.932–0.945) and in the 79–86 age group (AUROC 0.889). We present the first evidence that routinely collected secondary care health record data can be used in the general population to stratify patients at risk of first HHF.
- 18 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0314145
Open AccessEarly detection of heart failure using in-patient longitudinal electronic health records
Heart Failure (HF) is common, with worldwide prevalence of 1%-3% and a lifetime risk of 20% for individuals 40 years or older. Despite its considerable health economic burden, techniques for early detection of HF in the general population are sparse. In this work we tested the hypothesis that a simple Transformer neural network, trained on comprehensive collection of secondary care data across the general population, can be used to prospectively (three-year predictive window) identify patients at an increased risk of first hospitalisation due to HF (HHF). The model was trained using routinely-collected, secondary care health data, including patient demographics, A&E attendances, hospitalisations, outpatient data, medications, blood tests, and vital sign measurements obtained across five years of longitudinal electronic health records (EHRs). The training cohort consisted of n = 183,894 individuals (n = 161,658 age/sex-matched controls and n = 22,236 of first hospitalisation due to HF after a three-year predictive window). Model performance was validated in an independent testing set of n = 8,977 patients (n = 945 HHF patients). Testing set probabilities were well-calibrated and achieved good discriminatory power with Area Under Receiver Operating Characteristic Curve (AUROC]) of 0.86, sensitivity of 36.4% (95% CI: 33.33%-39.56%), specificity of 98.26% (95% CI: 97.95%-98.53%), and PPV of 69.88% (95% CI: 65.86%-73.62%). At Probability of HHF ≥ 90% the model achieved 100% PPV (95% CI: 96.73%-100%) and sensitivity of 11.7% (95% CI: 9.72%-13.91%). Performance was not affected by patient sex or socioeconomic deprivation deciles. Performance was significantly better in Asian, Black, and Mixed ethnicities (AUROC 0.932–0.945) and in the 79–86 age group (AUROC 0.889). We present the first evidence that routinely collected secondary care health record data can be used in the general population to stratify patients at risk of first HHF.
- Open Access
- 1 March 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 5 (2)
An Artificial Neural Network for Nasogastric Tube Position Decision Support
To develop and validate a deep learning model for detection of nasogastric tube (NGT) malposition on chest radiographs and assess model impact as a clinical decision support tool for junior physicians to help determine whether feeding can be safely performed in patients (feed/do not feed). A neural network ensemble was pretrained on 1 132 142 retrospectively collected (June 2007–August 2019) frontal chest radiographs and further fine-tuned on 7081 chest radiographs labeled by three radiologists. Clinical relevance was assessed on an independent set of 335 images. Five junior emergency medicine physicians assessed chest radiographs and made feed/do not feed decisions without and with artificial intelligence (AI)-generated NGT malposition probabilities placed above chest radiographs. Decisions from the radiologists served as ground truths. Model performance was evaluated using receiver operating characteristic analysis. Agreement between junior physician and radiologist decision was determined using the Cohen κ coefficient. In the testing set, the ensemble achieved area under the receiver operating characteristic curve values of 0.82 (95% CI: 0.78, 0.86), 0.77 (95% CI: 0.71, 0.83), and 0.98 (95% CI: 0.96, 1.00) for satisfactory, malpositioned, and bronchial positions, respectively. In the clinical evaluation set, mean interreader agreement for feed/do not feed decisions among junior physicians was 0.65 ± 0.03 (SD) and 0.77 ± 0.13 without and with AI support, respectively. Mean agreement between junior physicians and radiologists was 0.53 ± 0.05 (unaided) and 0.65 ± 0.09 (AI-aided). A simple classifier for NGT malposition may help junior physicians determine the safety of feeding in patients with NGTs. Keywords: Neural Networks, Feature Detection, Supervised Learning, Machine Learning Supplemental material is available for this article. Published under a CC BY 4.0 license.
- 1 March 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 5 (2)
Open AccessAn Artificial Neural Network for Nasogastric Tube Position Decision Support
To develop and validate a deep learning model for detection of nasogastric tube (NGT) malposition on chest radiographs and assess model impact as a clinical decision support tool for junior physicians to help determine whether feeding can be safely performed in patients (feed/do not feed). A neural network ensemble was pretrained on 1 132 142 retrospectively collected (June 2007–August 2019) frontal chest radiographs and further fine-tuned on 7081 chest radiographs labeled by three radiologists. Clinical relevance was assessed on an independent set of 335 images. Five junior emergency medicine physicians assessed chest radiographs and made feed/do not feed decisions without and with artificial intelligence (AI)-generated NGT malposition probabilities placed above chest radiographs. Decisions from the radiologists served as ground truths. Model performance was evaluated using receiver operating characteristic analysis. Agreement between junior physician and radiologist decision was determined using the Cohen κ coefficient. In the testing set, the ensemble achieved area under the receiver operating characteristic curve values of 0.82 (95% CI: 0.78, 0.86), 0.77 (95% CI: 0.71, 0.83), and 0.98 (95% CI: 0.96, 1.00) for satisfactory, malpositioned, and bronchial positions, respectively. In the clinical evaluation set, mean interreader agreement for feed/do not feed decisions among junior physicians was 0.65 ± 0.03 (SD) and 0.77 ± 0.13 without and with AI support, respectively. Mean agreement between junior physicians and radiologists was 0.53 ± 0.05 (unaided) and 0.65 ± 0.09 (AI-aided). A simple classifier for NGT malposition may help junior physicians determine the safety of feeding in patients with NGTs. Keywords: Neural Networks, Feature Detection, Supervised Learning, Machine Learning Supplemental material is available for this article. Published under a CC BY 4.0 license.
- Open Access
- 14 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
Development and prospective validation of COVID-19 chest X-ray screening model for patients attending emergency departments
Chest X-rays (CXRs) are the first-line investigation in patients presenting to emergency departments (EDs) with dyspnoea and are a valuable adjunct to clinical management of COVID-19 associated lung disease. Artificial intelligence (AI) has the potential to facilitate rapid triage of CXRs for further patient testing and/or isolation. In this work we develop an AI algorithm, CovIx, to differentiate normal, abnormal, non-COVID-19 pneumonia, and COVID-19 CXRs using a multicentre cohort of 293,143 CXRs. The algorithm is prospectively validated in 3289 CXRs acquired from patients presenting to ED with symptoms of COVID-19 across four sites in NHS Greater Glasgow and Clyde. CovIx achieves area under receiver operating characteristic curve for COVID-19 of 0.86, with sensitivity and F1-score up to 0.83 and 0.71 respectively, and performs on-par with four board-certified radiologists. AI-based algorithms can identify CXRs with COVID-19 associated pneumonia, as well as distinguish non-COVID pneumonias in symptomatic patients presenting to ED. Pre-trained models and inference scripts are freely available at https://github.com/beringresearch/bravecx-covid.
- 14 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
Open AccessDevelopment and prospective validation of COVID-19 chest X-ray screening model for patients attending emergency departments
Chest X-rays (CXRs) are the first-line investigation in patients presenting to emergency departments (EDs) with dyspnoea and are a valuable adjunct to clinical management of COVID-19 associated lung disease. Artificial intelligence (AI) has the potential to facilitate rapid triage of CXRs for further patient testing and/or isolation. In this work we develop an AI algorithm, CovIx, to differentiate normal, abnormal, non-COVID-19 pneumonia, and COVID-19 CXRs using a multicentre cohort of 293,143 CXRs. The algorithm is prospectively validated in 3289 CXRs acquired from patients presenting to ED with symptoms of COVID-19 across four sites in NHS Greater Glasgow and Clyde. CovIx achieves area under receiver operating characteristic curve for COVID-19 of 0.86, with sensitivity and F1-score up to 0.83 and 0.71 respectively, and performs on-par with four board-certified radiologists. AI-based algorithms can identify CXRs with COVID-19 associated pneumonia, as well as distinguish non-COVID pneumonias in symptomatic patients presenting to ED. Pre-trained models and inference scripts are freely available at https://github.com/beringresearch/bravecx-covid.
- Open Access
- 10 March 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3) , e0229963
Supervised and unsupervised language modelling in Chest X-Ray radiological reports
Chest radiography (CXR) is the most commonly used imaging modality and deep neural network (DNN) algorithms have shown promise in effective triage of normal and abnormal radiograms. Typically, DNNs require large quantities of expertly labelled training exemplars, which in clinical contexts is a major bottleneck to effective modelling, as both considerable clinical skill and time is required to produce high-quality ground truths. In this work we evaluate thirteen supervised classifiers using two large free-text corpora and demonstrate that bi-directional long short-term memory (BiLSTM) networks with attention mechanism effectively identify Normal, Abnormal, and Unclear CXR reports in internal (n = 965 manually-labelled reports, f1-score = 0.94) and external (n = 465 manually-labelled reports, f1-score = 0.90) testing sets using a relatively small number of expert-labelled training observations (n = 3,856 annotated reports). Furthermore, we introduce a general unsupervised approach that accurately distinguishes Normal and Abnormal CXR reports in a large unlabelled corpus. We anticipate that the results presented in this work can be used to automatically extract standardized clinical information from free-text CXR radiological reports, facilitating the training of clinical decision support systems for CXR triage.
- 10 March 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3) , e0229963
Open AccessSupervised and unsupervised language modelling in Chest X-Ray radiological reports
Chest radiography (CXR) is the most commonly used imaging modality and deep neural network (DNN) algorithms have shown promise in effective triage of normal and abnormal radiograms. Typically, DNNs require large quantities of expertly labelled training exemplars, which in clinical contexts is a major bottleneck to effective modelling, as both considerable clinical skill and time is required to produce high-quality ground truths. In this work we evaluate thirteen supervised classifiers using two large free-text corpora and demonstrate that bi-directional long short-term memory (BiLSTM) networks with attention mechanism effectively identify Normal, Abnormal, and Unclear CXR reports in internal (n = 965 manually-labelled reports, f1-score = 0.94) and external (n = 465 manually-labelled reports, f1-score = 0.90) testing sets using a relatively small number of expert-labelled training observations (n = 3,856 annotated reports). Furthermore, we introduce a general unsupervised approach that accurately distinguishes Normal and Abnormal CXR reports in a large unlabelled corpus. We anticipate that the results presented in this work can be used to automatically extract standardized clinical information from free-text CXR radiological reports, facilitating the training of clinical decision support systems for CXR triage.
- Open Access
- 1 March 2020
- Published by Elsevier in Advances in Medical Sciences
- Vol. 65 (1) , 18-29
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors
- 1 March 2020
- Published by Elsevier in Advances in Medical Sciences
- Vol. 65 (1) , 18-29
Open AccessThe clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors
- 14 December 2019
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (4) , 895-906
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Purpose Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-time. PPQ predicts PRRT efficacy; NETest monitors disease. We prospectively evaluated: (1) NETest as a surrogate biomarker for RECIST; (2) the correlation of NETest levels with PPQ prediction. Methods Three independent 177Lu-PRRT-treated GEP-NET and lung cohorts (Meldola, Italy: n = 72; Bad-Berka, Germany: n = 44; Rotterdam, Netherlands: n = 41). Treatment response: RECIST1.1 (responder (stable, partial, and complete response) vs non-responder). Blood sampling: pre-PRRT, before each cycle and follow-up (2–12 months). PPQ (positive/negative) and NETest (0–100 score) by PCR. Stable < 40; progressive > 40). CgA (ELISA) as comparator. Samples de-identified, measurement and analyses blinded. Kaplan–Meier survival and standard statistics. Results One hundred twenty-two of the 157 were evaluable. RECIST stabilization or response in 67%; 33% progressed. NETest significantly (p < 0.0001) decreased in RECIST “responders” (− 47 ± 3%); in “non-responders,” it remained increased (+ 79 ± 19%) (p < 0.0005). NETest monitoring accuracy was 98% (119/122). Follow-up levels > 40 (progressive) vs stable (< 40) significantly correlated with mPFS (not reached vs. 10 months; HR 0.04 (95%CI, 0.02–0.07). PPQ response prediction was accurate in 118 (97%) with a 99% accurate positive and 93% accurate negative prediction. NETest significantly (p < 0.0001) decreased in PPQ-predicted responders (− 46 ± 3%) and remained elevated or increased in PPQ-predicted non-responders (+ 75 ± 19%). Follow-up NETest categories stable vs progressive significantly correlated with PPQ prediction and mPFS (not reached vs. 10 months; HR 0.06 (95%CI, 0.03–0.12). CgA did not reflect PRRT treatment: in RECIST responders decrease in 38% and in non-responders 56% (p = NS). Conclusions PPQ predicts PRRT response in 97%. NETest accurately monitors PRRT response and is an effective surrogate marker of PRRT radiological response. NETest decrease identified responders and correlated (> 97%) with the pretreatment PPQ response predictor. CgA was non-informative.
- 14 December 2019
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (4) , 895-906
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Purpose Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-time. PPQ predicts PRRT efficacy; NETest monitors disease. We prospectively evaluated: (1) NETest as a surrogate biomarker for RECIST; (2) the correlation of NETest levels with PPQ prediction. Methods Three independent 177Lu-PRRT-treated GEP-NET and lung cohorts (Meldola, Italy: n = 72; Bad-Berka, Germany: n = 44; Rotterdam, Netherlands: n = 41). Treatment response: RECIST1.1 (responder (stable, partial, and complete response) vs non-responder). Blood sampling: pre-PRRT, before each cycle and follow-up (2–12 months). PPQ (positive/negative) and NETest (0–100 score) by PCR. Stable < 40; progressive > 40). CgA (ELISA) as comparator. Samples de-identified, measurement and analyses blinded. Kaplan–Meier survival and standard statistics. Results One hundred twenty-two of the 157 were evaluable. RECIST stabilization or response in 67%; 33% progressed. NETest significantly (p < 0.0001) decreased in RECIST “responders” (− 47 ± 3%); in “non-responders,” it remained increased (+ 79 ± 19%) (p < 0.0005). NETest monitoring accuracy was 98% (119/122). Follow-up levels > 40 (progressive) vs stable (< 40) significantly correlated with mPFS (not reached vs. 10 months; HR 0.04 (95%CI, 0.02–0.07). PPQ response prediction was accurate in 118 (97%) with a 99% accurate positive and 93% accurate negative prediction. NETest significantly (p < 0.0001) decreased in PPQ-predicted responders (− 46 ± 3%) and remained elevated or increased in PPQ-predicted non-responders (+ 75 ± 19%). Follow-up NETest categories stable vs progressive significantly correlated with PPQ prediction and mPFS (not reached vs. 10 months; HR 0.06 (95%CI, 0.03–0.12). CgA did not reflect PRRT treatment: in RECIST responders decrease in 38% and in non-responders 56% (p = NS). Conclusions PPQ predicts PRRT response in 97%. NETest accurately monitors PRRT response and is an effective surrogate marker of PRRT radiological response. NETest decrease identified responders and correlated (> 97%) with the pretreatment PPQ response predictor. CgA was non-informative.
- Open Access
- 7 November 2019
- Published by S. Karger AG in Neuroendocrinology
- Vol. 110 (5) , 322-327
The Use of Deep Learning and Neural Networks in Imaging: Welcome to the New Mathematical Milieu of Medicine
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- 7 November 2019
- Published by S. Karger AG in Neuroendocrinology
- Vol. 110 (5) , 322-327
Open AccessThe Use of Deep Learning and Neural Networks in Imaging: Welcome to the New Mathematical Milieu of Medicine
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Open Access
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (7) , 1878-1892.e7
Aryl Hydrocarbon Receptor Contributes to the Transcriptional Program of IL-10-Producing Regulatory B Cells
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (7) , 1878-1892.e7
Open AccessAryl Hydrocarbon Receptor Contributes to the Transcriptional Program of IL-10-Producing Regulatory B Cells
- Open Access
- 6 August 2019
- Published by The Open Journal in Journal of Open Source Software
- Vol. 4 (40)
ivis: dimensionality reduction in very large datasets using Siamese Networks
- 6 August 2019
- Published by The Open Journal in Journal of Open Source Software
- Vol. 4 (40)
Open Accessivis: dimensionality reduction in very large datasets using Siamese Networks
- Open Access
- 27 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0218592
Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis
Multigene-based PCR tests are time-consuming and limiting aspects of the protocol include increased risk of operator-based variation. In addition, such protocols are complex to transfer and reproduce between laboratories. Evaluate the clinical utility of a pre-spotted PCR plate (PSP) for a novel multigene (n = 51) blood-based gene expression diagnostic assay for neuroendocrine tumors (NETs). A pilot study (n = 44; 8 controls and 36 NETs) was undertaken to compare CQ, normalized gene expression and algorithm-based output (NETest score). Gene expression was then evaluated between matched blood:tumor tissue samples (n = 7). Thereafter, two prospective sets (diagnostic: n = 167; clinical validation: n = 48, respectively) were evaluated for diagnostic and clinical utility value. Two independent molecular diagnostics facilities were used to assess assay reproducibility and inter-laboratory metrics. Samples were collected (per CLIA protocol) processed to mRNA and cDNA and then either run per standard assay (liquid primers) or on PSPs. Separately, matching plasma samples were analyzed for chromogranin A (CgA). Statistics included non-parametric testing, Pearson-concordance, Predictive Modeling and AUROC analyses. In the pilot study (n = 44), CQ values were highly concordant (r: 0.82, ppn = 30 controls, n = 87 non-NET controls, n = 50 NET), NETest was significantly lower (pp96%) scores and was significantly better (p96%) NETest results. Moreover, it functions significantly more accurately than CgA.
- 27 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0218592
Open AccessUtility of a ready-to-use PCR system for neuroendocrine tumor diagnosis
Multigene-based PCR tests are time-consuming and limiting aspects of the protocol include increased risk of operator-based variation. In addition, such protocols are complex to transfer and reproduce between laboratories. Evaluate the clinical utility of a pre-spotted PCR plate (PSP) for a novel multigene (n = 51) blood-based gene expression diagnostic assay for neuroendocrine tumors (NETs). A pilot study (n = 44; 8 controls and 36 NETs) was undertaken to compare CQ, normalized gene expression and algorithm-based output (NETest score). Gene expression was then evaluated between matched blood:tumor tissue samples (n = 7). Thereafter, two prospective sets (diagnostic: n = 167; clinical validation: n = 48, respectively) were evaluated for diagnostic and clinical utility value. Two independent molecular diagnostics facilities were used to assess assay reproducibility and inter-laboratory metrics. Samples were collected (per CLIA protocol) processed to mRNA and cDNA and then either run per standard assay (liquid primers) or on PSPs. Separately, matching plasma samples were analyzed for chromogranin A (CgA). Statistics included non-parametric testing, Pearson-concordance, Predictive Modeling and AUROC analyses. In the pilot study (n = 44), CQ values were highly concordant (r: 0.82, ppn = 30 controls, n = 87 non-NET controls, n = 50 NET), NETest was significantly lower (pp96%) scores and was significantly better (p96%) NETest results. Moreover, it functions significantly more accurately than CgA.